Tripep’s rights offering

Tripep has finalized a rights offering with a maximum of 48 million units which fully subscribed would have given Tripep 24 MSEK before transaction costs. The rights issue has so far raised appr. 16 MSEK. 50.7 % has been subscribed and paid for using first rights. 3.4 % has been subscribed and paid for without rights. The rights offering was guaranteed equally between Erik Selin and Rutger Smith. Rutger Smith had also committed to subscribe for Verazzano Ltds’ rights share comprising approximately 19.8 % corresponding to approximately 4.8 MSEK.

Rutger Smith has informed Tripep that he owing to a liquidity problem cannot fulfill his obligation at the moment. Tripep will, however, pursue its demand on Rutger Smith. In view of the current situation Tripep will bring forward an already planned private placement in which Tripep’s management and people close to the company intend to participate.

”We receive continuous information from our ongoing phase I/II-study on ChronVac-C® where now three patients have been included. So far we have not seen any significant side effects. These are very encouraging study results, considering that this is one of the major challenges with this type of treatments. Seen in the light of this and the status of our other projects it is of course sad that one of our guarantors does not live up to his fulfillment, however, this does not directly affect any of our ongoing projects”, says Tripep’s CEO Jan Nilsson.



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se